Reversal of gene expression changes in the colorectal normal-adenoma pathway by NS398 selective COX2 inhibitor
Open Access
- 19 January 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 102 (4), 765-773
- https://doi.org/10.1038/sj.bjc.6605515
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Cyclooxygenase-2 Inhibitors Decrease Vascular Endothelial Growth Factor Expression in Colon Cancer Cells by Enhanced Degradation of Sp1 and Sp4 ProteinsMolecular Pharmacology, 2005
- COX-2: A Molecular Target for Colorectal Cancer PreventionJournal of Clinical Oncology, 2005
- Cyclooxygenase-2 increases hypoxia-inducible factor-1 and vascular endothelial growth factor to promote angiogenesis in gastric carcinomaJournal of Biomedical Science, 2005
- Cyclooxygenase-2 ExpressionClinical Cancer Research, 2004
- NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model1Journal of the American College of Surgeons, 2004
- Role of cancer-associated stromal fibroblasts in metastatic colon cancer to the liver and their expression profilesOncogene, 2004
- Expression profiling — best practices for data generation and interpretation in clinical trialsNature Reviews Genetics, 2004
- A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients.2003
- The colorectal adenoma–carcinoma sequenceBritish Journal of Surgery, 2002
- Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomasGastroenterology, 1994